Patent details

EP3682884 Title: CRYSTALLINE FORMS OF DAPRODUSTAT (GSK1278863), A PERORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) FOR TREATING ANEMIA, AND THEIR PREPARATION METHODS

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Unitary Effect

Unitary Effect Requested:
Yes
Unitary Effect Request Filing Date:
07/05/2024
Unitary Effect Status:
Unitary Effect Registered
Request Unitary Effect Accepted:
21/05/2024
Unitary Effect Date:
24/04/2024
Unitary Effect Registration Date:
21/05/2024
Request Unitary Effect Rejected:
Unitary Effect Re-establishment of rights Filing Date:
Unitary Effect Re-establishment of rights EPO Decision :
Unitary Effect Re-establishment of rights EPO Decision Date:
Unitary Effect Request Withdrawal Date:
Unitary Effect request has been accepted, please see the UPP register at the EPO for up-to-date information
UPP register:
EP3682884
SPC Number:
Creation Date:

Basic Information

Publication number:
EP3682884
WO Application Number:
CN2018078766
Type:
European Patent Granted for NL
Status:
Unitary Effect Registered
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP18857375.2
WO Publication Number:
WO2019052133
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
United Kingdom (GB)
Publications:

Dates

Filing date:
13/03/2018
Grant date:
24/04/2024
EP Publication Date:
22/07/2020
WO Publication Date:
21/03/2019
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
24/04/2024
EP B1 Publication Date:
24/04/2024
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
12/03/2038
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
24/04/2024
 
 

 

Name:
GlaxoSmithKline Intellectual Property (No. 2) Limited
Address:
GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom (GB)

Inventor

1

Name:
CHEN, Minhua
Address:
Suzhou Jiangsu 215123, China (CN)

2

Name:
ZHANG, Yanfeng
Address:
Suzhou Jiangsu 215123, China (CN)

3

Name:
WANG, Jinqiu
Address:
Suzhou Jiangsu 215123, China (CN)

4

Name:
ZHANG, Xiaoyu
Address:
Suzhou Jiangsu 215123, China (CN)

Priority

Priority Patent Number:
201710835313
Priority Date:
15/09/2017
Priority Country:
China (CN)

Classification

IPC or IDT classification:
C07D 239/62; A61K 31/515; A61P 7/06;

Publication

Bulletin

1

Bulletin Heading:
UP1
Journal edition number:
25/24
Publication date:
19/06/2024
Description:
European patents with registered Unitary Effect

2

Bulletin Heading:
EP2
Journal edition number:
17/24
Publication date:
24/04/2024
Description:
European patents granted for the Netherlands

European Patent Bulletin

1

Issue number:
202425
Publication date:
19/06/2024
Description:
Unitary Effect Request Acceptance

2

Issue number:
202424
Publication date:
12/06/2024
Description:
Unitary Effect Request Receipt

3

Issue number:
202417
Publication date:
24/04/2024
Description:
Grant (B1)

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type